我要投票 Singfiller欣菲聆在玻尿酸行业中的票数:143
· 外 推 电 报 ·
2025-02-27 02:01:08 星期四

【Singfiller欣菲聆是哪个国家的品牌?】

Singfiller欣菲聆是什么牌子?「Singfiller欣菲聆」是 杭州协合医疗用品有限公司 旗下著名品牌。该品牌发源于浙江,由创始人沈晶在2003期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Singfiller欣菲聆品牌出海!通过在本页面挂载Singfiller欣菲聆品牌的产品链接和联系邮箱,可以提高Singfiller欣菲聆产品曝光!跨境电商爆单神器,目前只要100元/年哦~

2002年,在富阳新登,杭州协合医疗用品有限公司迈出了属于它的第一步。至此,拉开了协合医疗十年发展的大幕。2003年协合医疗迁至富阳高桥工业园区,陆续建起万级净化车间2个、质检中心和研发中心各1个,仓库楼、宿舍楼各一幢,初步实现了由微小企业向中小型企业的过渡。

2011年协合医疗收购海纳医疗(杭州)有限公司,总投资3个亿,开始建设协合医疗下沙新基地,一期已经建成1.7万平方米的标准化厂房,2000平方米的GMP净化车间3个、4000平方米的物流中心、1000平方米的研发及质检中心,可生产各类医疗器械1200余万套,实现产能25亿人民币。截止2013年,协合医疗已拥有下沙、富阳、南昌三个生产基地,杭州、北京、上海、南昌、广州、成都、重庆、福州8个医学营销中心,北京、上海两家医学会展及培训公司,集团员工400余人,年产各类医疗械200多万套,年销售逾5亿人民币,成功实现由创业阶段向快速发展阶段的转型。

协合医疗目前有八大系列产品,每年50余种医疗器械产品销往30个省市,用户达1000余家,部分产品远销往全球40多个国家,如:意大利、俄罗斯、土耳其、法国、巴西、智利、澳大利亚、加拿大。作为以发展新型复合与智能型材料为方向的杭州协合医疗用品有限公司来说,它的坚持,正在备受认可。

协合医疗构建了与国际同步的可吸收生物材料研发平台,在防粘连、止血、微整形材料、组织工程基础材料领域已获得10余项专利,另有多项专利正在申报中。当然,除了产品的研发,严格的质量控制也是企业赖以生存的根本,协合医疗遵循“质量第一、管理优先、建和谐企业、创协合品牌”的质量方针,生产车间采用当代先进的制药工艺生产线和在线监控设备,以确保持续生产出符合国家食品药品监督管理总局(CFDA)法规要求和欧盟MDD指令的第三类医疗器械、药品注射剂产品。越来越多的荣誉,越来越多的新技术,越来越成熟的发展模式,杭州协合医疗用品有限公司正在一步步成为中国可吸收生物材料领域的领军者。

英文翻译:In 2002, in Xindeng, Fuyang, Hangzhou Xiehe Medical Supplies Co., Ltd. took its first step. So far, it has opened the curtain of the development of cooperative medical treatment in the past ten years. In 2003, Xiehe Medical moved to Fuyang Gaoqiao Industrial Park, successively built two 10000 level purification workshops, one quality inspection center and one R & D center, one warehouse building and one dormitory building, initially realizing the transition from small and medium-sized enterprises to small and medium-sized enterprises. In 2011, Xiehe Medical purchased Haina medical (Hangzhou) Co., Ltd. with a total investment of 300 million yuan, and started to build a new base of Xiehe Medical in Xiasha. In phase I, 17000 square meters of standardized factory buildings, 2000 square meters of GMP purification workshops, 4000 square meters of logistics centers and 1000 square meters of R & D and quality inspection centers have been built, which can produce more than 12 million sets of various medical devices and achieve a production capacity of 2.5 billion yuan RMB. As of 2013, Xiehe Medical Co., Ltd. has three production bases in Xiasha, Fuyang and Nanchang, eight medical marketing centers in Hangzhou, Beijing, Shanghai, Nanchang, Guangzhou, Chengdu, Chongqing and Fuzhou, two medical exhibition and training companies in Beijing and Shanghai, with more than 400 employees, an annual production of more than 2 million sets of various medical devices, and an annual sales of more than 500 million yuan. It has successfully realized the transformation from the entrepreneurial stage to the fast stage Transformation of rapid development stage. At present, Xiehe Medical has eight series of products, more than 50 kinds of medical device products are sold to 30 provinces and cities every year, with more than 1000 users. Some products are exported to more than 40 countries around the world, such as Italy, Russia, Turkey, France, Brazil, Chile, Australia and Canada. Hangzhou Xiehe Medical Supplies Co., Ltd., which aims to develop new composite and intelligent materials, is being recognized for its persistence. Synergetic medical has built an internationally synchronized research and development platform for absorbable biomaterials. It has obtained more than 10 patents in the fields of anti adhesion, hemostasis, micro plastic materials and basic materials for tissue engineering, and many other patents are under application. Of course, in addition to product research and development, strict quality control is also the foundation for the survival of enterprises. Xiehe Medical follows the quality policy of "quality first, management first, building a harmonious enterprise and creating Xiehe brand". The production workshop adopts the modern advanced pharmaceutical process production line and on-line monitoring equipment to ensure the continuous production in line with the State Food and Drug Administration (CFDA) Class III medical devices and drug injection products required by regulations and EU MDD directives. With more and more honors, more and more new technologies and more mature development models, Hangzhou Xiehe Medical Supplies Co., Ltd. is becoming the leader in the field of absorbable biomaterials in China step by step.

本文链接: https://www.waitui.com/brand/8f8f64f88.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

美股大型科技股盘前多数上涨,英伟达涨超2%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,英伟达涨超2%,特斯拉涨超1%,亚马逊涨0.9%,Meta涨0.84%,谷歌涨0.6%,微软涨0.37%,奈飞涨0.15%;苹果跌0.31%。

2分钟前

热门中概股美股盘前普涨,理想汽车涨超9%

36氪获悉,热门中概股美股盘前普涨,截至发稿,理想汽车涨超9%,小鹏汽车涨超8%,京东涨超7%,阿里巴巴、爱奇艺涨超4%,拼多多、微博涨超3%,百度、网易、蔚来涨超2%。

2分钟前

美国抵押贷款利率降至6.88%,创今年以来最低水平

美国抵押贷款利率上周降至今年以来的最低水平,但不足以刺激贷款活动反弹。美国抵押贷款银行家协会(MBA)周三公布的数据显示,截至2月21日当周,30年期抵押贷款的合约利率下降5个基点,至6.88%。抵押贷款利率跟随美国国债收益率,过去一周美债收益率下行,因为投资者在股票和原油石油遭遇抛售之际寻求避险。经济数据也导致近期收益率下降,这些数据包括1月份零售销售疲软、消费者对长期通胀率的预期升至1995年以来最高。(财联社)

2分钟前

巴奴火锅门店数量已超140家,创始人称上市是未来重要方向

日前,巴奴创始人杜中兵表示,部分消费者认为巴奴的价格偏高,未来我们将披露财务报表,让消费者更清晰地了解巴奴产品的价值。截至去年底,巴奴毛肚火锅已经在全国开设了超过140家直营门店,综合净利润率为9%,平均翻台率约为3.7次。上市也是巴奴火锅未来重要发展方向。(证券时报)

2分钟前

宗申动力:西藏国隆科技拟减持公司不超3%股份

36氪获悉,宗申动力发布公告,持股18.11%的股东西藏国隆科技有限公司计划以集中竞价方式和大宗交易方式,减持公司股份不超过3435.08万股(占公司总股本的3%)。公司董事李耀计划以集中竞价方式减持公司股份不超过4.24万股(占公司总股本的0.0037%)。

2分钟前

本页详细列出关于逆时光 INVERSE TIME的品牌信息,含品牌所属公司介绍,逆时光 INVERSE TIME所处行业的品牌地位及优势。
咨询